Amodiaquine
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Amodiaquine: From Malaria to Pulmonary Hypertension
One-Sentence Summary
Amodiaquine is an aminoquinoline antimalarial agent with known anti-inflammatory properties, originally used in the treatment and prophylaxis of malaria. The TxGNN model predicts it may be effective for Pulmonary Hypertension, with a prediction score of 99.25%; however, currently no clinical trials and no supporting literature directly link amodiaquine to this indication — this prediction rests entirely on computational modeling.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No registered indication in Saudi Arabia (antimalarial agent) |
| Predicted New Indication | Pulmonary Hypertension |
| TxGNN Prediction Score | 99.25% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological literature, amodiaquine belongs to the 4-aminoquinoline class — the same structural family as chloroquine and hydroxychloroquine. These drugs are established for their anti-inflammatory properties, primarily through suppression of pro-inflammatory cytokines including TNF-α and IL-6, as well as inhibition of lysosomal activity and Toll-like receptor signaling.
The proposed link to pulmonary hypertension rests on the hypothesis that aminoquinolines could attenuate pulmonary vascular inflammation — a recognized contributor to vascular remodeling in PAH (pulmonary arterial hypertension). Chloroquine, a close structural analog, has appeared in sporadic preclinical and in vitro reports exploring PAH-related pathways. However, no studies have directly examined amodiaquine's effects on pulmonary vascular biology or right heart function.
The mechanistic basis connecting amodiaquine specifically to pulmonary hypertension remains thin. The TxGNN prediction likely derives from shared knowledge graph pathways (aminoquinoline class → anti-inflammatory → vascular inflammation → PAH), rather than any direct experimental evidence. This makes the prediction biologically plausible but experimentally unvalidated.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for amodiaquine in pulmonary hypertension.
Saudi Arabia Market Information
Amodiaquine is not currently marketed in Saudi Arabia. No product authorizations are on record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is at Evidence Level L5 — generated solely by the TxGNN computational model with no supporting clinical trials or literature. Amodiaquine is not marketed in Saudi Arabia, and critical safety data (warnings, contraindications, drug interactions) are absent from this pack. The mechanistic link to pulmonary hypertension is indirect and class-inferred rather than drug-specific. Proceeding without foundational evidence would not meet any responsible repurposing threshold.
To proceed, the following is needed:
- MOA data: Retrieve full DrugBank pharmacology entry (DB00613) to confirm mechanism, targets, and known off-target effects
- Safety data: Obtain full prescribing information (package insert) including black-box warnings, hepatotoxicity risk profile, and known drug interactions — amodiaquine has historical agranulocytosis and hepatotoxicity concerns that must be characterized before any repurposing evaluation
- Preclinical evidence search: Targeted literature search for amodiaquine (or its active metabolite desethylamodiaquine) in pulmonary vascular models, PAH animal studies, or hypoxia-induced vascular remodeling
- Class evidence review: Systematic review of chloroquine/hydroxychloroquine data in PAH to establish aminoquinoline class plausibility before committing resources to amodiaquine-specific studies
- Regulatory pathway assessment: Since the drug is not marketed in Saudi Arabia, a full import/registration feasibility analysis is required before any clinical development can be considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.